Q&A: Can inhaled vaccines mount comeback for one-time leader in China's Covid race?
SAN FRANCISCO — In the still-unfolding chronicle of Covid-19 vaccine history, March 16, 2020 might bear an entry on how the NIH dosed the first volunteer with Moderna’s mRNA vaccine. Much less remembered, though, is the fact that on the same day, a then-11-year-old Chinese vaccine maker received the greenlight from regulators in China to begin its own first-in-human trial for an adenoviral vector-based shot.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.